
Slides: Management of CV Risk & T2DM: Implications of novel outcome trials
The slides are prepared and presented by the speaker during a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona. The files are an educational service to registered PACE members only. PACE is not responsible for the content, opinions expressed in the slides
Disclosures
Prof. John E Deanfield, MD is Professor of Cardiology, Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom
Funding
This symposium was supported by an unrestricted educational grant provided by Boehringer-Ingelheim/Lilly
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-CME.
Share this page with your colleagues and friends: